Mankind Pharma543904Pharmaceuticals
Jefferies and Kotak remain positive on Mankind Pharma after strong Q2 numbers
By ScoutQuest · · 1 min read
Heard on business television at 13:01:42 IST.
- Jefferies and Kotak cited robust domestic growth and improving earnings for Mankind Pharma.
- Brokerages remained positive on the stock following a strong set of second quarter numbers.
Watch at source
behind live
The exact mention could not be pinned down — start here and listen forward.
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Mankind Pharma
Mankind Pharma investor deck: FY26 revenue crosses ₹14.2k Cr, chronic share targeted at ~50% by FY30, 70% stake in Belgian CAR-T firm ACTx
27 Oct 2026
Mankind Pharma's strong Q2 results won brokerage support, with Jefferies and Kotak retaining buy ratings
27 Oct 2026
Mankind Pharma shares jumped 9% after Q2 earnings beat driven by strong domestic pharma growth and margin expansion
27 Oct 2026
Source: Live TV News Channel · 27 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.